Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma

BACKGROUND: Antibody-drug conjugates have recently been introduced as a treatment for advanced urothelial carcinoma. The EV-301 study demonstrated that enfortumab vedotin (EV) improved overall survival compared with conventional chemotherapy. To assess the cost-effectiveness of EV for the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Qiuji, Qin, Yi, Liao, Weiting, Zhang, Mengxi, Yang, Yang, Zhang, Pengfei, Li, Qiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Challenging Dogma: New Evidence to Guide Practice in Urologic Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796084/
https://www.ncbi.nlm.nih.gov/pubmed/35096146
http://dx.doi.org/10.1177/17588359211068733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796084/
https://www.ncbi.nlm.nih.gov/pubmed/35096146
http://dx.doi.org/10.1177/17588359211068733

Ejemplares similares